Zacks: Brokerages Expect Nabriva Therapeutics plc (NASDAQ:NBRV) Will Post Earnings of -$0.19 Per Share

Equities research analysts forecast that Nabriva Therapeutics plc (NASDAQ:NBRVGet Rating) will post ($0.19) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Nabriva Therapeutics’ earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.18). Nabriva Therapeutics posted earnings per share of ($0.29) in the same quarter last year, which suggests a positive year over year growth rate of 34.5%. The company is expected to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Nabriva Therapeutics will report full-year earnings of ($0.73) per share for the current financial year. For the next year, analysts expect that the firm will report earnings of ($0.37) per share, with EPS estimates ranging from ($0.40) to ($0.33). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow Nabriva Therapeutics.

Nabriva Therapeutics (NASDAQ:NBRVGet Rating) last posted its earnings results on Thursday, May 5th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). Nabriva Therapeutics had a negative net margin of 137.52% and a negative return on equity of 82.07%. During the same period in the previous year, the company earned ($0.53) earnings per share.

Several analysts have recently weighed in on the company. Northland Securities reduced their target price on Nabriva Therapeutics from $4.00 to $2.00 and set an “outperform” rating for the company in a report on Wednesday, March 30th. assumed coverage on Nabriva Therapeutics in a research report on Sunday. They issued a “hold” rating on the stock. Finally, Zacks Investment Research cut Nabriva Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, May 11th.

Several institutional investors and hedge funds have recently added to or reduced their stakes in NBRV. Advisor Group Holdings Inc. lifted its stake in Nabriva Therapeutics by 5,200.0% in the 3rd quarter. Advisor Group Holdings Inc. now owns 26,500 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 26,000 shares in the last quarter. Millennium Management LLC purchased a new stake in Nabriva Therapeutics in the 2nd quarter valued at approximately $42,000. Two Sigma Securities LLC purchased a new stake in Nabriva Therapeutics in the 3rd quarter valued at approximately $48,000. Geode Capital Management LLC lifted its stake in shares of Nabriva Therapeutics by 102.9% during the 3rd quarter. Geode Capital Management LLC now owns 42,738 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 21,672 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Nabriva Therapeutics during the 4th quarter worth $125,000. Institutional investors and hedge funds own 1.55% of the company’s stock.

Shares of Nabriva Therapeutics stock traded up $0.00 on Monday, hitting $0.19. The stock had a trading volume of 130 shares, compared to its average volume of 477,431. Nabriva Therapeutics has a 52-week low of $0.19 and a 52-week high of $2.32. The company has a current ratio of 4.01, a quick ratio of 2.94 and a debt-to-equity ratio of 0.09. The stock has a market cap of $121.10 million, a price-to-earnings ratio of -0.20 and a beta of 1.57. The company’s 50 day moving average price is $0.35 and its 200 day moving average price is $0.53.

About Nabriva Therapeutics (Get Rating)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.

Featured Stories

Get a free copy of the Zacks research report on Nabriva Therapeutics (NBRV)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with's FREE daily email newsletter.